Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumors


New Drug Shows Improved Outcomes for Patients with Advanced Metastatic Mid-gut Neuroendocrine Tumors (January 23, 2017)

A new therapy in development for the treatment of mid-gut neuroendocrine tumors, a rare type of cancer that occurs in the small intestine and colon, shows improved outcomes for patients with advanced disease... Continue Reading

Stivarga Approved for Advanced Gastrointestinal Stromal Tumors (March 12, 2013)

The U.S. Food and Drug Administration (FDA) expanded the approved use of Stivarga® (regorafenib)to treat patients with advanced gastrointestinal stromal tumors (GIST) that cannot be surgically removed... Continue Reading

Cancer Navigators Help Patients with Gastrointestional Stromal Tumors (March 17, 2012)

Cancer navigators offer patients with gastrointestional stromal tumors guidance as they find their way through a cancer journey. By Sally Abrahms In 1992 Anne McNerney was an insurance company executive... Continue Reading

Anemia: A Manageable Side Effect Gastrointestinal Stromal Tumors (October 25, 2011)

Anemia, one of the most common side effects associated with cancer, affects over 60 percent of cancer patients. Anemia may occur as either a direct result of the cancer or, more commonly, as a side effect... Continue Reading

Clinical Trial Participation Is Inadequate (August 31, 2011)

A large proportion of cancer patients do not enroll in clinical trials, and those who do participate may not adequately represent age groups, cancer stages, cancer types, and racial and ethnic groups.... Continue Reading

Preparing for Surgery (June 22, 2011)

You can help ensure that your surgery and recovery go smoothly and that you have the best outcome possible by preparing yourself ahead of time. Here are a few tips to keep you healthy and comfortable and... Continue Reading

Three Years of Treatment with Gleevec Improves Survival in Gastrointestinal Stromal Tumors (GIST) (June 9, 2011)

Treatment with Gleevec® (imatinib) for 3 years following surgery significantly improves survival compared with the standard one-year therapy for patients with gastrointestinal stromal tumors (GIST). GIST... Continue Reading

Know the Signs of Depression in Cancer Patients (April 7, 2011)

Because a significant number of cancer patients—an estimated 25 percent—experience major depression at some point during their illness, recognizing the signs of depression among patients is a critical... Continue Reading

Nexavar Shows Promise against Drug-Resistant GIST (February 1, 2011)

Among patients with gastrointestinal stromal tumors (GIST) that were resistant to both Gleevec® (imatinib) and Sutent® (sunitinib), treatment with Nexavar® (sorafenib) resulted in tumor shrinkage or... Continue Reading

Managing a Rare Cancer Diagnosis (November 18, 2009)

Managing a rare cancer diagnosis presents unique challenges. One survivor shares her tips for navigating the sometimes-murky waters. By Phyllis A. Domm, with Ashley and Chris Laub On January 7, I became... Continue Reading

What to Tell Children when Facing a Diagnosis of Cancer (November 18, 2009)

 If you have children in your life, you already know that they tend to be creatures of habit who rely on their daily routine. There may be unexpected changes in their routine with your fight against cancer,... Continue Reading

Gleevec® Approved for Adjuvant Treatment of Gastrointestinal Stromal Tumors (December 31, 2008)

Gleevec® Approved for Adjuvant Treatment of Gastrointestinal Stromal Tumors The U.S. Food and Drug Administration has expanded the approval of Gleevec® (imatinib mesylate) to include the adjuvant (post-surgery)... Continue Reading

Update in the Management of Gastrointestinal Stromal Tumors (GIST): A Report from ASCO 2007 (June 26, 2007)

Update in the Management of Gastrointestinal Stromal Tumors (GIST): A Report from ASCO 2007 June 1-4, 2007Chicago, IL Margaret von Mehren, MD Director Sarcoma Oncology, Fox Chase Cancer Center, Philadelphia,... Continue Reading

Gleevec® Confirmed as Effective Treatment for Early GIST (May 1, 2007)

Gleevec® Confirmed as Effective Treatment for Early GIST According to results from a large North American clinical trial, Gleevec® (imatinib mesylate) reduces the risk of a cancer recurrence following... Continue Reading

Interruption of Treatment with Gleevec® Not Recommended for GIST (March 23, 2007)

Interruption of Treatment with Gleevec® Not Recommended for GIST According to an article published in the Journal of Clinical Oncology, interruption in treatment with Gleevec® (imatinib mesylate) is... Continue Reading

Two-gene Test Correctly Distinguishes GIST from Leiomyosarcoma (February 28, 2007)

Two-gene Test Correctly Distinguishes GIST from Leiomyosarcoma According to the results of a study published in the Proceedings of the National Academy of Sciences, a test that assesses the expression... Continue Reading

Sutent® Improves Outcomes for Patients with GIST (October 11, 2006)

Sutent® Improves Outcomes for Patients with GIST According to an article recently published in The Lancet, Sutent® (sunitinib) improves outcomes among patients with gastrointestinal stromal tumor (GIST)... Continue Reading

Treatment of Gastrointestinal Stromal Tumors (October 2, 2006)

Overview Gastrointestinal stromal tumors (GISTs) are relatively rare cancers that originate in the cells of Cajal, which are specialized cells lining the digestive tract responsible for initiating the... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS